MREO
Mereo BioPharma Group plcCompany Information
- Company Name
- Mereo BioPharma Group plc
- CIK
- CIK0001719714
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- MREO: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MREO
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2024-09-13
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 610,750
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 56,349,084
- Shares outstanding
- 160,712,542
- Ownership
- 35.06%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -18.30%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 30 | 36 | 41 | 49 | 56 | 62 | 70 | 81 | 87 | 49 | 57 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 4 | 4 | 3 | 5 | ||||||
| Assets Current | 33 | 40 | 45 | 52 | 61 | 67 | 75 | 87 | 94 | 53 | 64 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Finite Lived Intangible Assets Net | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 35 | 41 | 46 | 54 | 63 | 68 | 76 | 89 | 96 | 56 | 66 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable Current | 1 | 3 | 1 | 1 | 1 | 3 | 2 | 2 | 3 | 2 | 2 | ||||||
| Accrued Liabilities Current | 2 | 2 | 2 | 4 | 5 | 3 | 4 | 4 | 4 | 3 | 5 | ||||||
| Convertible Notes Payable Current | - | - | 0 | 0 | 0 | 0 | 6 | 6 | 5 | 5 | 0 | ||||||
| Derivative Liabilities Current | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Current | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 1 | 1 | ||||||
| Liabilities Current | 6 | 6 | 4 | 6 | 8 | 7 | 14 | 14 | 15 | 11 | 9 | ||||||
| Convertible Long Term Notes Payable | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 4 | ||||||
| Derivative Liabilities Noncurrent | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 6 | 7 | 5 | 7 | 8 | 8 | 15 | 16 | 17 | 13 | 16 | ||||||
Stockholders Equity | |||||||||||||||||
| Common Stock Value | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Additional Paid In Capital | 552 | 551 | 550 | 548 | 546 | 544 | 540 | 536 | 535 | 487 | 486 | ||||||
| Treasury Stock Common Value | - | - | - | - | - | - | 0 | 0 | 0 | 0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -515 | -508 | -501 | -494 | -487 | -472 | -463 | -456 | -441 | -429 | -420 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -12 | -13 | -11 | -11 | -9 | -15 | -19 | -11 | -18 | -18 | -17 | ||||||
| Stockholders Equity | 29 | 34 | 41 | 47 | 54 | 60 | 61 | -73 | 79 | 43 | 51 | ||||||
| Liabilities And Stockholders Equity | 35 | 41 | 46 | 54 | 63 | 68 | 76 | 89 | 96 | 56 | 66 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Issued | 160 | 160 | 159 | 159 | 159 | 159 | 155 | 155 | 154 | 140 | 140 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMereo BioPharma Group plc (MREO) — SEC Financial Statements & Analysis
Mereo BioPharma Group plc (MREO) is a pharmaceutical preparations company, incorporated in X0. Mereo BioPharma Group plc trades on Nasdaq as: MREO. Mereo BioPharma Group plc (MREO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Mereo BioPharma Group plc carries a market cap of $51.11M, a P/E ratio of -1.82x, a P/B ratio of 1.78x, a P/S ratio of -331.86x, an enterprise value of $20.99M, and an EV/EBITDA multiple of -0.62x. On profitability, it posts a gross margin of 43.51%, an operating margin of 22209.09%, a net margin of 18246.10%, a Return on Equity (ROE) of -67.85%, and a Return on Assets (ROA) of -57.73%. Per share, it reports EPS of $-0.17, diluted EPS of $-0.17, free cash flow per share of $-0.16, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -130.80% year-over-year, net income growth of -43.29% year-over-year, and EPS growth of -43.58% year-over-year. On the balance sheet, it maintains a current ratio of 5.88x, a quick ratio of 5.60x, working capital of $27.72M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.17, an interest coverage ratio of -393.13x, free cash flow of $-25.65M (TTM), and net debt of $-30.12M. Figures sourced from SEC EDGAR.
- Market Cap
- $51.11M
- P/E TTM
- -1.82x
- EPS TTM
- $-0.17
- P/B TTM
- 1.78x
- ROE TTM
- -67.85%
- ROA TTM
- -57.73%
- Debt To Equity
- 0.21x
- Free Cash Flow TTM
- $-25.65M
- Net Revenue TTM Growth 1Y
- -130.80%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Mereo BioPharma Group plc in?
Mereo BioPharma Group plc (MREO) operates in the Pharmaceutical Preparations industry.
What exchange does MREO trade on?
Mereo BioPharma Group plc (MREO) trades on the Nasdaq.
Where is Mereo BioPharma Group plc incorporated?
Mereo BioPharma Group plc is incorporated in United Kingdom.
When was Mereo BioPharma Group plc (MREO)'s most recent SEC filing?
Mereo BioPharma Group plc (MREO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is MREO's market cap?
Mereo BioPharma Group plc (MREO) has a market capitalization of $51.11M as of 2026-06-30.
What is MREO's EPS (earnings per share)?
Mereo BioPharma Group plc (MREO)'s trailing twelve month EPS is $-0.17 as of 2026-06-30.
What is MREO's ROE (return on equity)?
Mereo BioPharma Group plc (MREO)'s trailing twelve month Return on Equity (ROE) is -67.85% as of 2026-06-30.
What is MREO's ROA (return on assets)?
Mereo BioPharma Group plc (MREO)'s trailing twelve month Return on Assets (ROA) is -57.73% as of 2026-06-30.
What is MREO's EV/EBITDA?
Mereo BioPharma Group plc (MREO)'s trailing twelve month EV/EBITDA is -0.62x as of 2026-06-30.